Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit

[1]  Dennis Andersson,et al.  Ensuring trust in COVID-19 data , 2021, Medicine.

[2]  N. Safdar,et al.  Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis , 2021, PloS one.

[3]  G. d’Ettorre,et al.  Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection , 2021, Chemotherapy.

[4]  G. d’Ettorre,et al.  Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic , 2021, Internal and Emergency Medicine.

[5]  P. Luethy,et al.  Rapid Spread and Control of Multidrug-Resistant Gram-Negative Bacteria in COVID-19 Patient Care Units , 2021, Emerging infectious diseases.

[6]  Wei Yang,et al.  A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19 , 2021, medRxiv.

[7]  P. Póvoa,et al.  Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study , 2021, Intensive Care Medicine.

[8]  G. d’Ettorre,et al.  Post-Traumatic Stress Symptoms in Healthcare Workers Dealing with the COVID-19 Pandemic: A Systematic Review , 2021, International journal of environmental research and public health.

[9]  L. Carrozzi,et al.  Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study , 2020, The Journal of antimicrobial chemotherapy.

[10]  T. Welte,et al.  Current evidence for COVID-19 therapies: a systematic literature review , 2020, European Respiratory Review.

[11]  G. d’Ettorre,et al.  Comparison Between Hospitalized Patients Affected or Not Affected by Coronavirus Disease 2019 , 2020, Clinical Infectious Diseases.

[12]  S. Harbarth,et al.  Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  Yue Dong,et al.  Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review , 2020, Mayo Clinic Proceedings.

[14]  P. Póvoa,et al.  Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review , 2020, Clinical Microbiology and Infection.

[15]  M. Bassetti,et al.  Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study , 2020, Infectious Diseases and Therapy.

[16]  O. Pajot,et al.  Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU , 2020, Annals of Intensive Care.

[17]  Á. Avezum,et al.  Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. , 2020, JAMA.

[18]  G. Mutlu,et al.  Late onset infectious complications and safety of tocilizumab in the management of COVID‐19 , 2020, Journal of medical virology.

[19]  Felipe García,et al.  Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study , 2020, Clinical Microbiology and Infection.

[20]  W. Lima,et al.  Ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19: Two problems, one solution? , 2020, Medical Hypotheses.

[21]  Zigui Chen,et al.  Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19 , 2020, Gut.

[22]  D. Hanauer,et al.  Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  D. Hanauer,et al.  Tocilizumab for treatment of mechanically ventilated patients with COVID-19 , 2020, medRxiv.

[24]  J. Bengoechea,et al.  SARS‐CoV‐2, bacterial co‐infections, and AMR: the deadly trio in COVID‐19? , 2020, EMBO molecular medicine.

[25]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[26]  A. Russo.  Spotlight on New Antibiotics for the Treatment of Pneumonia , 2020, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.

[27]  C. Mussini,et al.  Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. , 2019, The Journal of infection.

[28]  R. Bonomo,et al.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections , 2018, Antimicrobial Agents and Chemotherapy.

[29]  M. Bassetti,et al.  Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria , 2018, Current opinion in critical care.

[30]  E. Pérez-Nadales,et al.  Risks of Infection and Mortality Among Patients Colonized With Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae: Validation of Scores and Proposal for Management , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  M. Venditti,et al.  Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients , 2018, Antimicrobial Agents and Chemotherapy.

[32]  R. Bonomo,et al.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges , 2016, Clinical Microbiology Reviews.

[33]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[34]  Adil Rafiq Rather,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .

[35]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.